Article
[Fullerene Doxorubicin Nanotransporter for Target Interaction with mutated gene BRCA2].
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti - 1 Jan 2000
Skaličková S, Löfelmann M, Gargulák M, Dočekalová M, Ruttkay-Nedecký B, Suchý P, Kepinská M, Kizek R
Abstract excerpt
BACKGROUND: Malignant breast tumors are in developed countries, the most common cancer affecting mainly women. It is estimated that approximately 5-10% of breast cancers are conditioned by genetic family burdens, caused by mutation in the BRCA2 gene. In the course of the treatment doxorubicin is frequently used therapeutics. Despite its therapeutic efficacy, however, it shows high cardiotoxicity. Possibility to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.